

**November 10, 2023**

To,  
The Corporate Relationship Department,  
BSE Limited,  
Phiroze Jeejeebhoy Towers,  
Dalal Street,  
Mumbai – 400001  
**Scrip Code:** 540737

**Dear Sir / Ma'am,**

**Sub.: Outcome of Board Meeting held on November 10, 2023.**

With reference to the captioned subject matter, we would like to inform you that the Board of Directors of the Company at its meeting held today i.e., November 10, 2023 has inter alia considered and approved following:

1. Unaudited Financial Results of the Company for the quarter and half year ended on September 30, 2023, along with the limited review report of Auditors thereon pursuant to regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“SEBI LODR”). *The copy of the said financial results along with the limited review report of Auditors are enclosed herewith.*
2. Resignation of Mr. Jayesh Savjani (DIN 07740486), as a Non-Executive Independent Director of the Company with effect from November 10, 2023.
3. Resignation of Ms. Vaishaliben Vadodariya (DIN 08061214), as a Non-Executive Independent Director of the Company with effect from November 10, 2023.
4. the reconstitution of the following Committees of the Board of Directors w.e.f November 10, 2023.

**A. The Audit Committee:**

Sr No	Name of the Committee Member	Position	Category
1.	Maulikkumar Jaysukhbhai Sudani	Chairperson	Non-Executive Independent Director -
2.	Priyam Surendra Shah	Member	Non-Executive Independent Director -
3.	Chandulal Manubhai Kothia	Member	Executive Director
4.	Parulben Sahani	Member	Non-Executive Independent Director -

### B. The Nomination & Remuneration Committee:

Sr No	Name of the Committee Member	Position	Category
1.	Maulikkumar Jaysukhbhai Sudani	Chairperson	Non-Executive Independent Director -
2.	Priyam Surendra Shah	Member	Non-Executive Independent Director -
3.	Parulben Sahani	Member	Non-Executive Independent Director -

### C. The Stakeholders Relationship Committee:

Sr No	Name of the Committee Member	Position	Category
1.	Maulikkumar Jaysukhbhai Sudani	Chairperson	Non-Executive Independent Director -
2.	Chandulal Manubhai Kothia	Member	Executive Director
3.	Gunjan Chandulal Kothia	Member	Executive Director
4.	Priyam Surendra Shah	Member	Non-Executive Independent Director -

### D. The Corporate Social Responsibility Committee:

Sr No	Name of the Committee Member	Position	Category
1.	Chandulal Manubhai Kothia	Chairperson	Executive Director
2.	Maulikkumar Jaysukhbhai Sudani	Member	Non-Executive Independent Director -
3.	Gunjan Chandulal Kothia	Member	Executive Director
4.	Parulben Sahani	Member	Non-Executive Independent Director -

### E. The Management Committee:

Sr No	Name of the Committee Member	Position	Category
1.	Chandulal Manubhai Kothia	Chairperson	Executive Director
2.	Gunjan Chandulal Kothia	Member	Executive Director
3.	Parth Chandulal Kothia	Member	Executive Director
4.	Maulikkumar Jaysukhbhai Sudani	Member	Non-Executive Independent Director -

Further, the details required under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI Circular No. CIR/ CFD/ CMD/4/2015 dated 9<sup>th</sup> September, 2015 are enclosed as Annexure.

The meeting of the Board of Directors of the Company commenced at 07.30 p.m. and concluded at 09.50 p.m.

Kindly take the same on your record.

Thanking you,  
Yours Faithfully,

**For Shree Ganesh Remedies Limited**

**Sunny Narwani**  
**Company Secretary**



**Head Office (Unit-1) :**

Plot No. 6011-12, GIDC Estate,  
Ankleshwar - 393 002, Gujarat (INDIA)  
Ph.: +91 9614961469, 7574976076  
**CIN No. : L24230GJ1995PLC025661**

**Unit-2 :**

Plot No. 6714/2,-6715 GIDC Estate,  
Ankleshwar - 393 002, Gujarat (INDIA)  
Ph.: +91 9614961469, 7574976076  
**GSTIN : 24ABACS1471R1ZQ (Zero)**

**Unit-5 :**

Plot No. D-2/17/16,  
GIDC Estate,  
Dahej-II, Ta. Vagra,  
Gujarat (INDIA)



**Annexure**

**Disclosure required pursuant to Regulation 30 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with Para A of Schedule III to the said Regulations, with regard to change in Directors and Key Managerial Personnel is given herein under: -**

<b>Sr. No.</b>	<b>Particulars</b>	<b>Resignation of Mr. Jayesh Savjani, as a Non-Executive Independent Director</b>	<b>Resignation of Ms. Vaishaliben Vadodariya, as a Non-Executive Independent Director</b>
1.	Reason for change viz appointment, resignation, removal, death or otherwise	Resignation of Mr. Jayesh Savjani, as a Non-Executive Independent Director	Resignation of Ms. Vaishaliben Vadodariya, as a Non-Executive Independent Director
2.	Date of appointment/cessation (as applicable) & term of appointment	Resignation of Ms. Vaishaliben Vadodariya, as a Non-Executive Independent Director is effective from November 10, 2023.	Resignation of Mr. Jayesh Savjani, as a Non-Executive Independent Director is effective from November 10, 2023.
3.	Brief profile (in case of appointment)	N.A.	N.A.
4.	Disclosure of relationships between directors (in case of appointment of a director).	-	-
5.	Letter of Resignation along with detailed reasons for resignation	Attached	Attached
6.	Names of the listed Company in which the resigning director holds directorships, indicating the category of directorship & membership of board committees	NA	NA
7.	Confirmation that there are no other material reasons other than those mentioned in the resignation letter	Ms. Vaishaliben Vadodariya has confirmed that there are no material reasons for her resignation other than those mentioned in her resignation letter.	Mr. Jayesh Savjani has confirmed that there are no material reasons for his resignation other than those mentioned in his resignation letter.

**Independent Auditor's Review Report on Unaudited Quarterly and Year to Date Financial Results of Shree Ganesh Remedies Limited pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015**

**To the Board of Directors,  
Shree Ganesh Remedies Limited**

1. We have reviewed the accompanying Statement of Unaudited Standalone Financial Results of **Shree Ganesh Remedies Limited** ("the Company") for the quarter ended September 30, 2023 and for the year to date period from April 1, 2023 to September 30, 2023 ("the Statement"), being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations").
2. This Statement, which is the responsibility of the Company's Management and approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standards (Ind AS) 34, "Interim Financial Reporting" prescribed under Section 133 of the Companies Act, 2013 read with the relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagement (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.
4. Based on our review conducted as stated in paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Ind AS and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of the Listing Regulations, as amended from time to time, including the manner in which it is to be disclosed, or that it contains any material misstatement.

**MONARK BHAYLAL  
PADMANI**

Digitally signed by MONARK  
BHAYLAL PADMANI  
Date: 2023.11.10 21:16:44  
+05'30'

---

Mumbai | Delhi | Surat

5. We draw attention to Note 9 to the accompanying statement, which describes the restatement of reclassification made to the comparative financial information, in accordance with the principles of Ind AS 8 on “Accounting Policies, Changes in Accounting Estimates and Errors”.

Our conclusion is not modified in respect of this matter.

**Other Matter**

6. The comparative financial information of the Company for the quarter ended June 30, 2023, for the quarter ended September 30, 2022 & year to date period from April 1, 2022 to September 30, 2022, and for the year ended March 31, 2023 included in the Statement, have been reviewed/ audited by the predecessor auditor. The report of the predecessor auditor on the comparative financial information dated July 31, 2023, October 23, 2022 and May 30, 2023, respectively expressed an unmodified conclusion/opinion.

Our conclusion is not modified in respect of this matter.

For **BANSI S. MEHTA & CO.**  
Chartered Accountants  
Firm Registration No. 100991W

**MONARK  
BHAYLAL  
PADMANI** Digitally signed by  
MONARK BHAYLAL  
PADMANI  
Date: 2023.11.10  
21:17:04 +05'30'

**MONARK B. PADMANI**

Partner

Membership No. 185781

UDIN : 23185781BHABER2420

**PLACE:** Ankleshwar

**DATED:** November 10, 2023



SHREE GANESH REMEDIES LIMITED  
Manufacturer of API Intermediates & Speciality Chemicals

## Statement of Unaudited Financial Results For the Quarter and Half Year Ended 30TH SEPTEMBER 2023

ALL AMOUNTS ARE ₹ IN LAKHS EXCEPT SHARE DATA AND WHERE OTHERWISE STATED

Particulars	Sr. No	Quarter Ended			Half Year Ended		Year Ended
		30th September 2023	30th June 2023	30th September 2022	30th September 2023	30th September 2022	31st March 2023
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
<b>INCOME</b>							
Revenue from operations	I	3341.53	2671.96	2125.96	6013.49	3889.82	9021.96
Other Income	II	80.48	71.89	72.55	136.19	137.16	313.80
<b>Total Income (I+II)</b>	<b>III</b>	<b>3422.01</b>	<b>2743.85</b>	<b>2198.51</b>	<b>6149.68</b>	<b>4026.98</b>	<b>9335.76</b>
<b>EXPENSES</b>							
Cost of Material Consumed	IV	1391.90	1753.33	1176.83	3145.23	2361.41	4782.71
Purchase of Stock in trade		Nil	Nil	Nil	Nil	Nil	Nil
Changes in inventories of finished goods/ WIP		407.54	(361.99)	(101.75)	45.55	(393.20)	(68.84)
Employee Benefit Expense		194.32	159.25	137.59	353.56	275.31	587.08
Finance Costs		1.24	0.67	(14.39)	1.92	4.73	11.58
Depreciation and Amortisations		140.91	103.72	91.78	244.63	175.29	378.64
Other Expenses		425.24	441.85	378.97	850.91	684.91	1386.15
<b>Total Expenses</b>		<b>2561.17</b>	<b>2096.83</b>	<b>1669.03</b>	<b>4641.82</b>	<b>3109.32</b>	<b>7077.33</b>
Profit / (Loss) before Tax (III - IV)	V	860.84	647.02	529.48	1507.86	918.53	2258.43
<b>Tax Expenses</b>	<b>VI</b>						
Current Tax		198.48	170.00	136.50	368.48	240.77	584.84
Deferred Tax		6.97	1.91	(0.67)	8.87	(2.60)	(28.43)
Profit / (Loss) for the Period (V - VI)	VII	655.39	475.12	393.65	1130.51	680.36	1702.02
<b>OTHER COMPREHENSIVE INCOME</b>	<b>VIII</b>						
Income relating to item that will not be classified to profit and loss		4.33	Nil	Nil	4.33	Nil	Nil
Income Tax Relating to above		1.09	Nil	Nil	1.09	Nil	Nil
Income relating to item that will be classified to profit and loss		Nil	Nil	Nil	Nil	Nil	Nil
<b>Total Comprehensive Income for the period</b>		<b>5.42</b>	<b>Nil</b>	<b>Nil</b>	<b>5.42</b>	<b>Nil</b>	<b>Nil</b>
Weighted Avg. Paid Up Equity Share Capital (Face Value ₹ 10 each)		1230.93	1230.93	1200.67	1230.93	1200.67	1227.75
Other Equity Excluding Revaluation Reserves		Nil	Nil	Nil	Nil	Nil	7642.62
<b>Earning Per Share for Continuing operation</b>							
Basic EPS (₹)		5.32	3.86	3.28	9.18	5.67	13.86
Diluted EPS (₹)		5.32	3.86	3.28	9.18	5.67	13.86

For, Shree Ganesh Remedies Limited

CHANDULAL MANUBHAI KOTHIA Digitally signed by CHANDULAL MANUBHAI KOTHIA

Chandul Kothia  
Chairman and Managing Director  
DIN NO - 00652806

Ankleshwar  
10th November 2023

MONARK  
BHAYLAL  
PADMANI

Digitally signed by  
MONARK BHAYLAL  
PADMANI  
Date: 2023.11.10  
21:14:52 +05'30'



**Head Office (Unit-1) :**  
Plot No. 6011-12, GIDC Estate,  
Ankleshwar - 393 002, Gujarat (INDIA)  
Ph.: +91 9614961469, 7574976076  
**CIN No. : L24230GJ1995PLC025661**

**(Unit-2) :**  
Plot No. 6714/2, -6715 GIDC Estate,  
Ankleshwar - 393 002, Gujarat (INDIA)  
Ph.: +91 9614961469, 7574976076  
**GSTIN : 24ABACS1471R1ZQ (Zero)**



www.ganeshremedies.com  
WEBSITE

contact@ganeshremedies.com | EMAIL

## Unaudited Balance Sheet As At 30TH SEPTEMBER 2023

ALL AMOUNTS ARE ₹ IN LAKHS EXCEPT SHARE DATA AND WHERE OTHERWISE STATED

	AS AT 30th SEPTEMBER 2023 Unaudited	AS AT 31st MARCH 2023 Audited
<b>ASSETS</b>		
<b>1. Non-Current Assets</b>		
(a) Property, Plant and Equipment	3961.15	2085.65
(b) Capital work-in-progress	504.15	4176.64
(c) Right-of-use Assets	4209.44	1306.09
(d) Other Intangible Assets	30.85	54.69
(f) Financial Assets		
(i) Investments	8.00	8.00
(ii) Loans	Nil	Nil
(iii) Other Financial Assets	140.06	133.70
(g) Deferred Tax Assets (Net)	7.82	8.47
(h) Other Non Current Assets	76.25	76.25
<b>Total Non-Current Assets</b>	<b>8937.72</b>	<b>7954.21</b>
<b>2. Current Assets</b>		
(a) Inventories	2028.10	1817.60
(b) Financial Assets		
(i) Loans	149.35	201.12
(ii) Trade Receivable	2327.99	2794.56
(iii) Cash and Cash Equivalents	729.41	865.02
(iv) Bank Balances other than (iii) of above	Nil	250.00
(v) Other Financial Assets	Nil	Nil
(vi) Investments	506.28	Nil
(c) Current Tax Assets (Net)	912.57	503.13
<b>3. Asset held-for-sale</b>	<b>Nil</b>	<b>102.45</b>
<b>Total Current Assets</b>	<b>6653.69</b>	<b>6429.15</b>
<b>TOTAL ASSETS</b>	<b>15591.41</b>	<b>14383.36</b>
<b>EQUITY AND LIABILITIES</b>		
<b>1. Equity</b>		
(a) Equity Share Capital	1251.10	1251.10
(b) Other Equity	8715.68	7642.62
	<b>9966.78</b>	<b>8893.72</b>
<b>2. Liabilities</b>		
(A) Non Current Liabilities		Nil
(a) Financial Liabilities		
(i) Borrowings	3253.37	3093.24
(ia) Lease Liabilities	Nil	Nil
(ii) Trade payable	Nil	Nil
(b) Provisions	29.41	22.40
(c) Deferred Tax Liabilities (Net)	7.13	Nil
(d) Other Non Current liabilities	Nil	Nil
<b>Total Non Current Liabilities</b>	<b>3289.91</b>	<b>3115.63</b>
(B) Current Liabilities		
(a) Financial Liabilities		
(i) Borrowings	565.54	257.50
(ia) Lease Liabilities	Nil	Nil
(ii) Trade Payable	654.42	1453.39
(iii) Other Financial Liabilities	Nil	Nil
(b) Other Current Liabilities	Nil	Nil
(c) Provisions	161.44	78.27
(d) Current Tax Liabilities (Net)	953.32	584.84
<b>Total Current Liabilities</b>	<b>2334.72</b>	<b>2374.00</b>
<b>Total Liabilities</b>	<b>5624.63</b>	<b>5489.64</b>
<b>TOTAL EQUITY AND LIABILITIES</b>	<b>15591.41</b>	<b>14383.36</b>

For, Shree Ganesh Remedies Limited

CHANDULAL MANUBHAI KOTHIA  
Digitally signed by CHANDULAL MANUBHAI KOTHIA

Chandulal Kothia  
Chairman and Managing Director  
DIN NO - 00652806  
Ankleshwar  
10th November 2023

MONARK  
BHAYLAL  
PADMANI

Digitally signed by MONARK BHAYLAL PADMANI  
Date: 2023.11.10  
21:14:25 +05'30'



Head Office (Unit-1) :  
Plot No. 6011-12, GIDC Estate,  
Ankleshwar - 393 002, Gujarat (INDIA)  
Ph.: +91 9614961469, 7574976076  
CIN No. : L24230GJ1995PLC025661

(Unit-2) :  
Plot No. 6714/2, -6715 GIDC Estate,  
Ankleshwar - 393 002, Gujarat (INDIA)  
Ph.: +91 9614961469, 7574976076  
GSTIN : 24ABACS1471R120 (Zero)



www.ganeshremedies.com  
WEBSITE  
contact@ganeshremedies.com | EMAIL



## Cash Flow Statement For the Half Year Ended 30TH SEPTEMBER 2023

ALL AMOUNTS ARE ₹ IN LAKHS EXCEPT SHARE DATA AND WHERE OTHERWISE STATED

	AS AT 30th SEPTEMBER 2023 Unaudited	AS AT 30th SEPTEMBER 2022 Unaudited
<b>Profit Before Tax</b>	<b>1507.86</b>	<b>918.53</b>
<b>Cash Flows from Operating Activities</b>		
<b>Non Cash Items</b>		
Depreciation and Amortisations	244.63	178.38
Non cash income or exps	(53.07)	(2,762)
<b>Change in Working Capital</b>		
(Decrease)/ Increase in Provision	(350.07)	(256.61)
Increase/ (Decrease) in Creditor	(798.97)	(43.81)
Increase/ (Decrease) in Other Current liabilities	308.04	Nil
Decrease / (Increase) in Inventories	(210.50)	(504.29)
(Increase) / Decrease in Loan & Advances		524.86
(Increase) / Decrease in Debtors	466.58	318.14
(Increase) / Decrease in Other Current Assets	(506.28)	Nil
<b>Net Cash generated from operating activities</b>	<b>653.63</b>	<b>(1,627.23)</b>
<b>Cash Flows from Investing Activities</b>		
Deposit	250.00	(377.55)
Fixed Assets	(1199.38)	(324.77)
<b>Net Cash generated from Investing Activities</b>	<b>(949.38)</b>	<b>(702.32)</b>
<b>Cash Flows from Financing Activities</b>		
Secured Loans	160.13	1310.47
Unsecured Loans	Nil	897.25
<b>Net Cash generated from Financing Activities</b>	<b>160.13</b>	<b>2207.72</b>
<b>Net increase / decrease in cash and cash equivalents</b>	<b>(135.62)</b>	<b>(121.83)</b>
Cash and Cash equivalents at the beginning of the period	865.02	328.23
<b>Cash and Cash equivalents at the end of the period</b>	<b>729.41</b>	<b>206.40</b>

Particulars	AS AT 30th SEPTEMBER 2023	AS AT 30th SEPTEMBER 2022
Cash & Cash Equivalent comprises of		
Balances with bank		
In current Account	701.95	205.61
Cash on hand	0.26	0.79
Working Capital Facility From Bank	27.20	Nil
<b>Cash and Cash equivalents at the end of the period</b>	<b>729.41</b>	<b>206.40</b>

**For, Shree Ganesh Remedies Limited**

CHANDULAL MANUBHAI KOTHIA  
Digitally signed by  
CHANDULAL MANUBHAI  
KOTHIA

Chandulal Kothia

Chairman and Managing Director

DIN NO - 00652806

Ankleshwar

10th November 2023

**MONARK BHAYLAL PADMANI**  
Digitally signed by  
MONARK BHAYLAL  
PADMANI  
Date: 2023.11.10  
21:15:14 +05'30'



**Head Office (Unit-1) :**  
Plot No. 6011-12, GIDC Estate,  
Ankleshwar - 393 002, Gujarat (INDIA)  
Ph.: +91 9614961469, 7574976076  
CIN No. : L24230GJ1995PLC025661

**(Unit-2) :**  
Plot No. 6714/2,-6715 GIDC Estate,  
Ankleshwar - 393 002, Gujarat (INDIA)  
Ph.: +91 9614961469, 7574976076  
GSTIN : 24ABACS1471R12Q (Zero)



www.ganeshremedies.com  
WEBSITE  
contact@ganeshremedies.com  
E M A I L

**UNAUDITED FINANCIAL RESULTS-** For The Half Year Ended  
September 2023

ALL AMOUNTS IN LAKHS (₹), EXCEPT SHARE DATA AND WHERE OTHERWISE STATED

**NOTES**

1. The above results have been reviewed by the Audit Committee and approved by the Board of Directors in their meeting held on 10<sup>th</sup> November, 2023 and reviewed by the Statutory Auditors of the company.
2. The Company had adopted Indian Accounting Standards (IND AS) notified by Ministry of Corporate Affairs with Effect from 1st April 2017. Financial results for the quarter and six month ended on 30th September 2023 and quarter ended 30th June 2023 have been prepared accordingly. Financial Results for the quarter ended on 30th September 2022 have also been prepared in accordance with IND AS. The IND AS compliant results for the quarter and six month ended on 30th September 2023 have not been audited by the statutory auditors and provided their limited review. However, the management has exercised necessary due diligence to ensure that the financial results provide true and fair view of the Company's affairs.
3. As required under Regulation 33 of SEBI (LODR) Regulations, 2015 the limited review by the statutory auditors have been completed for the quarter ended on 30th September 2023. The report does not have any impact on the above results and notes which needs explanation. The above results have been reviewed and recommended by the Audit Committee on 10th November 2023 and subsequently approved by the Board of Directors at its meeting held on 10th November 2023.
4. Earning per shares: Earning per shares are has been calculated on the weighted average of the share capital outstanding during the quarter ended September 2023 as per Ind AS -33 Earnings Per Share.
5. The Company elected to exercise the option permitted under Section 115BAA of the Income Tax Act, 1961 as introduced by the Taxation Laws (Amendment) Ordinance, 2019. Accordingly, the Company had recognized the provision for income tax quarter and six month ended on on 30th September 2023 and 30th September 2022 and re-measured its deferred tax basis the rate prescribed in the said section.
6. The company is primarily engaged in the business of Bulk Drug Intermediates, which constitute a single reportable segment in accordance with Ind AS 108 - "Segment Reporting".
7. Kamalam Foundation is incorporated under Section 8 of the Companies Act, 2013 and it is prohibited to give any right over their profits to the members. In view of restrictions on Section 8 companies, the parent Company's share in Kamalam Foundation has not been considered and hence the consolidated financial statement are not prepared.

**8. Rights Issue Fund Utilisation Statement:**

Original Object	Original Allocation (₹ in Lakh)	Fund Utilised in Q4 FY2022-23 (₹ in Lakh)	Funds Utilised in Q1 FY 2023-24 (₹ in Lakh)	Funds Utilised in Q2 FY 2023-24 (₹ in Lakh)	Remarks if any
Part repayment or prepayment of unsecured loans availed from the Promoters and from the member of the Promoter Group	774.62	774.62	Nil	Nil	
Meeting incremental working capital requirements	150.00	Nil	150.00	Nil	
General corporate purposes	155.00	68.77	86.33		Rs 67.88 lacs utilized for repayment of borrowing in Q4 FY 2022-23
Issue related expenses	55.00	35.29	0.31	Nil	
<b>Total</b>	<b>1134.62</b>	<b>878.68</b>	<b>236.64</b>	<b>Nil</b>	

**9. The financial information for the previous reporting periods were restated for reclassification of certain items in accordance with Ind AS 8 on “Accounting Policies, Changes in Accounting Estimates and Errors” which are detailed as below:**

- Pending performance of services, sum of ₹ 76.25 lakhs paid in advance for Common Effluent Treatment Plant, construction of effluent pipeline and provisional membership of water contribution for Dahej Plant is reclassified as “Other Non-current assets” under the head “Noncurrent assets” from “Other Intangible Assets” as at 31st March, 2023.
- Amounts of Income under the head “Other Income” required to be adjusted against expenses is reclassified to “Other Expenses” as shown below:

**Impact:**

	Quarter Ended 30 <sup>th</sup> June, 2023 (Unaudited)	Quarter Ended 30 <sup>th</sup> September, 2022 (Unaudited)	Half year ended 30 <sup>th</sup> September, 2022 (Unaudited)	Year ended 31 <sup>st</sup> March, 2023 (Audited)
<b>Income:</b>				
Other Income	(1.08)	(0.14)	(0.87)	(2.67)

₹ In lakhs

<b>Expenses:</b>				
Other Expenses	(1.08)	(0.14)	(0.87)	(2.67)
<b>Impact</b>	<b>NIL</b>	<b>NIL</b>	<b>NIL</b>	<b>NIL</b>

- iii. Amortisation of land is reclassified as “Depreciation and Amortisation” from “Other Expenses” as shown below:

**Impact:**

₹ In lakhs

	Quarter Ended 30 <sup>th</sup> June, 2023 (Unaudited)	Quarter Ended 30 <sup>th</sup> September, 2022 (Unaudited)	Half year ended 30 <sup>th</sup> September, 2022 (Unaudited)	Year ended 31 <sup>st</sup> March, 2023 (Audited)
<b>Expenses:</b>				
Other Expenses	(1.55)	(1.55)	(3.10)	(6.19)
Depreciation and Amortisation	1.55	1.55	3.10	6.19
<b>Impact</b>	<b>NIL</b>	<b>NIL</b>	<b>NIL</b>	<b>NIL</b>

- iv. Trade Receivables of ₹ 2.28 lakhs is reclassified as “Trade Receivable” under the head “Current Assets” from “Other Non-current assets” under the head “Non-current assets” as at 31<sup>st</sup> March, 2023.
- v. Property, Plant and Equipment of ₹ 1306.09 lakhs is reclassified as “Right-of-use Assets” from “Property, Plant and Equipment” under the head “Non-current assets” as at 31<sup>st</sup> March, 2023.

10. Previous year / Period figures have been re-grouped, re-arranged wherever considered necessary.

For, Shree Ganesh Remedies Limited

CHANDULAL  
MANUBHAI KOTHIA

Digitally signed by  
CHANDULAL  
MANUBHAI KOTHIA

**Chandulal Kothia**

**Chairman and Managing Director**

DIN NO – 00652806

**Ankleshwar**

**10<sup>th</sup> November, 2023**

**MONARK**  
**BHAYLAL**  
**PADMANI**

Digitally signed by  
MONARK  
BHAYLAL  
PADMANI  
Date: 2023.11.10  
21:16:01 +05'30'

**November 10, 2023**

To,  
The Board of Directors  
**Shree Ganesh Remedies Limited**  
Plot No. 6011, G.I.D.C., Ankleshwar - 393002

**Sub: - Resignation from the position of an Independent Director of the Company.**

Dear Sir,

I, Jayesh Kishanlal Savjani, tender my resignation as an Independent Director of the Company to be considered with effect from November 10, 2023 due to my pre occupation.

Further, due to my resignation from the position of an independent Director of the Company, I also resign or vacate my position as member of various committees of the Board.

Pursuant to Clause 7B of Para A of Part A of Schedule III to the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015, I hereby confirm that my resignation is due to reason cited above and there is no other material reason other than those stated by me.

Kindly intimate the Stock Exchange and other Regulatory Authorities and arrange to submit the necessary forms for intimating my resignation with the office of the Registrar of the Companies, Gujarat.

Thanking you,  
Yours faithfully,



**Jayesh Kishanlal Savjani**  
**DIN: 07740486**

**November 10, 2023**

To,  
The Board of Directors  
**Shree Ganesh Remedies Limited**  
Plot No. 6011, G.I.D.C., Ankleshwar - 393002

**Sub: - Resignation as an Independent Director of the Company.**

Dear Sir/Ma'am,


I, Vaishaliben Kanjibhai Vadodariya, tender my resignation as an Independent Director of the Company to be considered with effect from November 10, 2023 due to re-location.

Further, due to my resignation from the position of an independent Director of the Company, I also resign or vacate my position as member of various committees of the Board.

Pursuant to Clause 7B of Para A of Part A of Schedule III to the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015, I hereby confirm that my resignation is due to reason cited above and there is no other material reason other than those stated by me.

Kindly acknowledge the receipt of my notice of resignation and intimate the Stock Exchange and other Regulatory Authorities and arrange to submit the necessary forms for intimating my resignation with the office of the Registrar of the Companies, Gujarat.

Thanking you,  
Yours faithfully,



**Vaishaliben Kanjibhai Vadodariya**  
**DIN: 08061214**